PsychExchange is a collection of in-depth conversations with the scientists, business executives, and legal experts paving the way to a new era of psychedelic medicine. If you’re aware of the main talking points of psychedelic science, but want to take a deeper approach; if you are considering getting involved in research or business; if you want to learn about the innovations in psychedelic science straight from the horse’s mouth, this podcast is for you.
PsychExchange Podcast
Claim This Podcastby Adrienne Jo & Sophie Rogers
5.0(12 reviews)
5 episodes
Updated Inactive
Accepts GuestsHas Sponsors
Podcast Overview
PsychExchange is a collection of in-depth conversations with the scientists, business executives, and legal experts paving the way to a new era of psychedelic medicine. If you’re aware of the main talking points of psychedelic science, but want to take a deeper approach; if you are considering getting involved in research or business; if you want to learn about the innovations in psychedelic science straight from the horse’s mouth, this podcast is for you.
Language
🇺🇲
Publishing Since
2/1/2023
1 verified contact email on file for PsychExchange Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
December 14, 2023
The Legal Trip: Protecting Psychedelic Innovations with Dr. Gretchen Temeles
<p>Imagine this - you’re in the lab and you’ve just discovered a novel psychedelic compound. It shows promising results in treating depressive symptoms with minimal side effects in your mouse model of depression. You may be on the brink of a groundbreaking therapeutic discovery and aspire to commercialize your finding into a biotech startup. But before diving forward, there’s a catch - the world of intellectual property and patents.</p> <p>In today’s episode, we delve into the complex yet crucial world of psychedelic intellectual property. What exactly patents, why are they essential in safeguarding your innovations? How do they compare with data exclusivity in protecting your technology? </p> <p>There’s no better person to guide us through this maze than our guest expert, Gretchen Temeles, Ph.D, J.D. Dr. Temeles is an experienced intellectual property attorney with extensive experience in counseling clients in the psychedelics and cannabis space in formulating comprehensive global IP strategies. She has also advised universities, startups, mid market companies, and multinational corporations, and is also a thought leader, serving on the Scientific Advisory Board of Palo Santo VC, a psychedelic therapeutics investment fund. </p> <p>Dr. Temeles combines her legal expertise with her scientific background as a former group leader in a biotech company focused on small molecule drug discovery in therapeutic areas that included neurological disorders, inflammation, cancer and infectious disease. This unique blend of skills makes her an ideal guide to understanding the importance of robust intellectual property protection, especially in the burgeoning field of psychedelic therapeutics.</p>
March 1, 2023
Remodeling the Mind with Dr. Alex Kwan
<p>The term “neuroplasticity” has become inextricably linked to the concept of how psychedelics may give rise to their therapeutic effects. But what really <em>is </em>neuroplasticity, and how can scientists measure it in the lab? How does pre-clinical research on rodent models permit a deeper understanding into the underlying mechanisms of how psychedelic treatments work? How does the primary psychotropic compound in psilocybin, commonly referred to as “Magic Mushrooms,” affect neuroplasticity, and may this be linked to adaptive behaviors?</p> <p>Tune in as Dr. Alex Kwan, Associate Professor at Cornell University, discusses how <a href="https://alexkwanlab.org/research/"><u>his laboratory</u></a> has leveraged key techniques in cellular, circuit, and behavioral neuroscience to help uncover the neuroplastic mechanisms of psilocybin in preclinical models of psychiatric disease.</p> <p><strong>__________________</strong></p> <p><strong>Dr. Kwan’s bio:</strong></p> <p>“I am an associate professor in the Meinig School of Biomedical Engineering at Cornell University. I received a Ph.D. in Applied Physics from Cornell University, where I worked on nonlinear optical microscopy in the laboratory of Watt Webb. For postdoctoral studies, I was a Croucher Fellow studying cortical microcircuits with Yang Dan at the University of California, Berkeley. Before joining the Cornell faculty in 2022, I was an associate professor in the Department of Psychiatry at Yale School of Medicine. The Kwan lab applies systems neuroscience and neuroengineering approaches to the study of mental health. We develop optical imaging techniques to visualize neural dynamics in awake mice. We design quantitative decision-making paradigms to characterize behavior. We often complement the imaging and behavioral experiments with other molecular, electrophysiological, optogenetic, and computational methods. Current effort in the lab is directed towards two topics: (1) Drug action in the brain: Psychiatric drugs exert powerful effects in humans characterized by altered perception, cognition, and mood. The lab studies the action of psychoactive drugs, including ketamine and serotonergic psychedelics such as psilocybin, on the function and connectivity of neurons in the frontal cortex. (2) Decision-making: Animals use past choice and reward history to guide their current decisions. We are interested in how neural circuits may implement reinforcement learning, and whether reward learning dysfunctions may be a useful metric to quantify neuropsychiatric conditions.” - engineering.cornell.edu.</p> <p><strong>Further reading:</strong></p> <p>Recent publications from the Kwan lab:</p> <p><a href="https://alexkwanlab.org/wp-content/uploads/2021/03/savaliaTINS2021.pdf"><u>A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.</u></a></p> <p><a href="https://alexkwanlab.org/wp-content/uploads/2021/08/shaoNeuron2021.pdf"><u>Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.</u></a></p> <p><a href="https://alexkwanlab.org/wp-content/uploads/2021/01/aliNatComm2020.pdf"><u>Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines.</u></a></p> <p><a href="https://www.biorxiv.org/content/10.1101/2022.03.18.484437v1"><u>Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin.</u></a></p> <p>Upcoming publications:</p> <p>The neural basis of psychedelic action.</p> <p>Kwan AC, Olson DE, Preller KH, and Roth BL.</p> <p>Psychedelics and neural plasticity: therapeutic implications.</p> <p>Grieco SF, Castrén E, Knudsen GM, Kwan AC, Olson DE, Zuo Y, Holmes TC, and Xu X.</p>
February 15, 2023
Teaching Old Drugs New Tricks with Jeffrey Becker, MD
<p><strong>The opioid epidemic both arises from and perpetuates a global crisis in pain treatment: How can we effectively treat pain while reducing the impact of addiction on individuals and society? Is ketamine the answer?</strong></p> <p><strong>In this episode, Dr. Jeffrey Becker, the CSO of </strong><a href="https://bexsonbiomedical.com/"><u><strong>Bexson Biomedical</strong></u></a><strong> discusses their novel insulin pump-inspired delivery system for ketamine, ketamine’s application to chronic pain, and what inspired him to explore the clinical applications of psychedelics.</strong></p> <p>“Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He was one of the first MDs in U.S. administering and documenting ketamine for depression in the clinic, and is a world recognized speaker and expert in the clinical use of ketamine. His expertise led to development of an effective nutraceutical product addressing NMDA-receptor abnormalities. He received his B.S. from UC Berkeley and M.D from UCLA. He maintains a clinical practice focused in Functional Psychiatry and novel treatment approaches to mental health challenges.” - bexsonbiomedical.com</p> <p><strong>Further reading:</strong></p> <p>Bexson Biomedical’s patent application:</p> <p><a href="https://patents.justia.com/patent/10973780"><u>https://patents.justia.com/patent/10973780</u></a></p> <p>Ketamine in the pain clinic:</p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/36034601/"><u>Peri-operative ketamine reduces post-operative opioid requirements.</u></a></p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271565/"><u>A review of impact of ketamine on pain perception and one’s relationship towards pain.</u></a></p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/35431578/"><u>A meta-analysis of clinical studies investigating the efficacy of ketamine for chronic pain.</u></a></p>
5 total episodes available
Deep-dive analytics for PsychExchange Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is PsychExchange Podcast?
- How often does this podcast release new episodes?
This podcast updates inactive.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.